Zepbound

• Higher doses of Zepbound to be offered on Eli Lilly website

  The company said the 12.5 milligrams and 15 mg doses of the drug will be available for US$499 per month on the website with shipments to self-paying patients.

  Consumer

  Jun 16
  
• Drugs like Ozempic may lower cancer risk if you have diabetes: study

  Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

  Health

  May 23
  
• Advertisement
• Zepbound beats Wegovy rival in 1st head-to-head weight loss study

  People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

  Health

  May 12
• Advertisement
• Biden proposes coverage for weight-loss drugs for millions of obese Americans

  While the rule would give millions of people access to weekly injectables that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.

  Health

  Nov 26, 2024
• Eli Lilly’s weight-loss drug cuts diabetes risk, long-term study finds

  The three-year study of tirzepatide found adults with prediabetes and obesity or overweight taking the drug weekly saw the risk of progression to diabetes lower by 94 per cent.

  Health

  Aug 20, 2024
• What is Zepbound? Could the weight-loss drug work better than Ozempic?

  Zepbound has been approved in the U.S. for weight loss, and studies show it could be the best-performing obesity drug to date.

  Health

  Nov 10, 2023